Forma Life Sciences Inc. today announced its launch as an independent contract development and manufacturing organization (CDMO).
The new entity was formed through BioSelective Capital Investments’ acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, which was announced last month. The acquired operations include two facilities totaling more than 100,000 square feet.
Forma Life Sciences will focus on oral solid dosage formulation development, clinical manufacturing and commercial drug product manufacturing in the U.S.
It will be led by Cyrus K. Mirsaidi as executive chairman and chief executive. He previously served as CEO of BioDuro from 2015 to 2021.
